Glynne-Jones R, Chait I, Thomas SF When and how to discharge cancer survivors in long term remission from follow-up: the effectiveness of a contract. Clin Oncol (R Coll Radiol). 1997;9(1):25-9.
Gupta SK Intention-to-treat concept: A review. Perspect Clin Res. 2011 Jul;2(3):109-12. doi: 10.4103/2229-3485.83221.
Horowitz M, Wilner N, Alvarez W Impact of Event Scale: a measure of subjective stress. Psychosom Med. 1979 May;41(3):209-18.
Humphris G, Ozakinci G The AFTER intervention: a structured psychological approach to reduce fears of recurrence in patients with head and neck cancer. Br J Health Psychol. 2008 May;13(Pt 2):223-30. doi: 10.1348/135910708X283751. Review.
Lebel S, Rosberger Z, Edgar L, Devins GM Comparison of four common stressors across the breast cancer trajectory. J Psychosom Res. 2007 Sep;63(3):225-32. Epub 2007 Aug 2.
Lebel S, Tomei C, Feldstain A, Beattie S, McCallum M Does fear of cancer recurrence predict cancer survivors' health care use? Support Care Cancer. 2013 Mar;21(3):901-6. doi: 10.1007/s00520-012-1685-3. Epub 2012 Dec 27.
Lebel, S & Maheu. C. (2009). Development of a cognitive-existential intervention to address fear of cancer recurrence in women with cancer. Unpublished manuscript.
Lee-Jones C, Humphris G, Dixon R, Hatcher MB Fear of cancer recurrence--a literature review and proposed cognitive formulation to explain exacerbation of recurrence fears. Psychooncology. 1997 Jun;6(2):95-105. Review.
Llewellyn CD, Weinman J, McGurk M, Humphris G Can we predict which head and neck cancer survivors develop fears of recurrence? J Psychosom Res. 2008 Dec;65(6):525-32. doi: 10.1016/j.jpsychores.2008.03.014. Epub 2008 Sep 24.
Lucock, M P., & Morley, S. (1996). The health anxiety questionnaire. British Journal of Health Psychology, 1(2), 137-150. doi: 10.1111/j.2044-8287.1996.tb00498.x
Mishel MH The measurement of uncertainty in illness. Nurs Res. 1981 Sep-Oct;30(5):258-63.
Savard J, Ivers H The evolution of fear of cancer recurrence during the cancer care trajectory and its relationship with cancer characteristics. J Psychosom Res. 2013 Apr;74(4):354-60. doi: 10.1016/j.jpsychores.2012.12.013. Epub 2013 Jan 26.
Sexton KA, Dugas MJ The Cognitive Avoidance Questionnaire: validation of the English translation. J Anxiety Disord. 2008;22(3):355-70. Epub 2007 Apr 25.
Simard S, Savard J, Ivers H Fear of cancer recurrence: specific profiles and nature of intrusive thoughts. J Cancer Surviv. 2010 Dec;4(4):361-71. doi: 10.1007/s11764-010-0136-8. Epub 2010 Jul 10.
Simard S, Savard J Fear of Cancer Recurrence Inventory: development and initial validation of a multidimensional measure of fear of cancer recurrence. Support Care Cancer. 2009 Mar;17(3):241-51. doi: 10.1007/s00520-008-0444-y. Epub 2008 Apr 15.
Urbaniak, G C., & Plous, S. (2007). Research randomizer. Retrieved from http://www.randomizer.org
Vickberg SM The Concerns About Recurrence Scale (CARS): a systematic measure of women's fears about the possibility of breast cancer recurrence. Ann Behav Med. 2003 Winter;25(1):16-24.
Efficacy of a Cognitive-Existential Therapy Intervention to Address Fear of Recurrence in Men and Women With Cancer: A Randomized Clinical Trial
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.